This observational study aims to find ways to detect Chronic Kidney Disease (CKD), Acute Rejection (AR), and Hepatitis C Virus (HCV) early in people who have received a liver transplant. Researchers will test blood, urine, and tissue samples to look for specific markers (proteogenomic biomarkers) that could show these conditions. Early detection of CKD, AR, and HCV could lead to more successful treatments and potentially reduce the need for repeat organ transplants. The study plans to enroll 1000 participants who are at least 18 years old and have had a liver transplant. The study is looking for biomarkers related to the RAF mechanism.

Study design

This is an observational study planning to enroll 1000 participants. It is not specified if there are different treatment groups or blinding.

What's involved

Participants will provide blood, urine, and tissue samples, likely at the time of a liver biopsy.

Compensation

Not stated in the trial record.

Follow-up

Proteogenomic biomarkers for CKD, AR, and HCV will be measured at the time of liver biopsy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.